AVIR logo

Atea Pharmaceuticals Inc. (AVIR)

$4.49

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AVIR

Market cap

$359321675

EPS

-2.11

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.323407

Price on AVIR

Previous close

$4.35

Today's open

$4.35

Day's range

$4.34 - $4.52

52 week range

$2.78 - $6.45

Profile about AVIR

CEO

Jean-Pierre Sommadossi

Employees

56

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

80027099

Issue type

Common Stock

AVIR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AVIR

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion of patient enrollment in C-FORWARD, its Phase 3 clinical trial outside North America, evaluating the regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) infection. The anticipated topline results from C-BEYOND, the Phase 3 trial conducted in the US and Canada, remain on track for mid-year 2026.

news source

GlobeNewsWire • Jun 25, 2026

news preview

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know

Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

news source

Zacks Investment Research • Jun 18, 2026

news preview

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Jun 9, 2026

news preview

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR's BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR's $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie.

news source

Seeking Alpha • May 29, 2026

news preview

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin.

news source

GlobeNewsWire • May 27, 2026

news preview

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

news source

Zacks Investment Research • May 15, 2026

news preview

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 13, 2026

news preview

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.

news source

GlobeNewsWire • May 13, 2026

news preview

Atea Pharmaceuticals Q1 Earnings Call Highlights

Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options.

news source

MarketBeat • May 12, 2026

news preview

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026 Company Holding Conference Call Today at 4:30 pm ET BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “With two pivotal Phase 3 readouts for our HCV program on the horizon, 2026 will be a catalyst-rich year for Atea,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.

news source

GlobeNewsWire • May 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Atea Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Atea Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AVIR on M1